182 related articles for article (PubMed ID: 37827216)
1. Cell Plasticity in a Mouse Model of Benign Prostate Hyperplasia Drives Amplification of Androgen-Independent Epithelial Cell Populations Sensitive to Antioxidant Therapy.
Dos Santos L; Carbone F; Pacreau E; Diarra S; Luka M; Pigat N; Baures M; Navarro E; Anract J; Barry Delongchamps N; Cagnard N; Bost F; Nemazanyy I; Petitjean O; Hamaï A; Ménager M; Palea S; Guidotti JE; Goffin V
Am J Pathol; 2024 Jan; 194(1):30-51. PubMed ID: 37827216
[TBL] [Abstract][Full Text] [Related]
2. Targeting stromal androgen receptor suppresses prolactin-driven benign prostatic hyperplasia (BPH).
Lai KP; Huang CK; Fang LY; Izumi K; Lo CW; Wood R; Kindblom J; Yeh S; Chang C
Mol Endocrinol; 2013 Oct; 27(10):1617-31. PubMed ID: 23893956
[TBL] [Abstract][Full Text] [Related]
3. Rate of castration-induced prostate stroma regression is reduced in a mouse model of benign prostatic hyperplasia.
Zhang R; Singh S; Pan C; Xu B; Kindblom J; Eng KH; Krolewski JJ; Nastiuk KL
Am J Clin Exp Urol; 2023; 11(1):12-26. PubMed ID: 36923722
[TBL] [Abstract][Full Text] [Related]
4. Prostate hyperplasia in a transgenic mouse with prostate-specific expression of prolactin.
Kindblom J; Dillner K; Sahlin L; Robertson F; Ormandy C; Törnell J; Wennbo H
Endocrinology; 2003 Jun; 144(6):2269-78. PubMed ID: 12746285
[TBL] [Abstract][Full Text] [Related]
5. Androgens and estrogens in benign prostatic hyperplasia: past, present and future.
Nicholson TM; Ricke WA
Differentiation; 2011; 82(4-5):184-99. PubMed ID: 21620560
[TBL] [Abstract][Full Text] [Related]
6. Gene expression analysis of prostate hyperplasia in mice overexpressing the prolactin gene specifically in the prostate.
Dillner K; Kindblom J; Flores-Morales A; Shao R; Törnell J; Norstedt G; Wennbo H
Endocrinology; 2003 Nov; 144(11):4955-66. PubMed ID: 12960074
[TBL] [Abstract][Full Text] [Related]
7. A new experimental rat model of erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: the testosterone-supplemented spontaneously hypertensive rat.
Oudot A; Oger S; Behr-Roussel D; Caisey S; Bernabé J; Alexandre L; Giuliano F
BJU Int; 2012 Nov; 110(9):1352-8. PubMed ID: 22448674
[TBL] [Abstract][Full Text] [Related]
8. Targeting androgen receptor to suppress macrophage-induced EMT and benign prostatic hyperplasia (BPH) development.
Lu T; Lin WJ; Izumi K; Wang X; Xu D; Fang LY; Li L; Jiang Q; Jin J; Chang C
Mol Endocrinol; 2012 Oct; 26(10):1707-15. PubMed ID: 22915828
[TBL] [Abstract][Full Text] [Related]
9. Review of the Roles and Interaction of Androgen and Inflammation in Benign Prostatic Hyperplasia.
Tong Y; Zhou RY
Mediators Inflamm; 2020; 2020():7958316. PubMed ID: 33192175
[TBL] [Abstract][Full Text] [Related]
10. 5-Alpha reductase inhibitors induce a prostate luminal to club cell transition in human benign prostatic hyperplasia.
Joseph DB; Henry GH; Malewska A; Reese JC; Mauck RJ; Gahan JC; Hutchinson RC; Mohler JL; Roehrborn CG; Strand DW
J Pathol; 2022 Apr; 256(4):427-441. PubMed ID: 34928497
[TBL] [Abstract][Full Text] [Related]
11. Sex steroid receptor expression and localization in benign prostatic hyperplasia varies with tissue compartment.
Nicholson TM; Sehgal PD; Drew SA; Huang W; Ricke WA
Differentiation; 2013; 85(4-5):140-9. PubMed ID: 23792768
[TBL] [Abstract][Full Text] [Related]
12. Glucocorticoids are induced while dihydrotestosterone levels are suppressed in 5-alpha reductase inhibitor treated human benign prostate hyperplasia patients.
Jin R; Forbes C; Miller NL; Strand D; Case T; Cates JM; Kim HH; Wages P; Porter NA; Mantione KM; Burke S; Mohler JL; Matusik RJ
Prostate; 2022 Oct; 82(14):1378-1388. PubMed ID: 35821619
[TBL] [Abstract][Full Text] [Related]
13. The prostaglandin pathway is activated in patients who fail medical therapy for benign prostatic hyperplasia with lower urinary tract symptoms.
Jin R; Strand DW; Forbes CM; Case T; Cates JMM; Liu Q; Ramirez-Solano M; Milne GL; Sanchez S; Wang ZY; Bjorling DE; Miller NL; Matusik RJ
Prostate; 2021 Sep; 81(13):944-955. PubMed ID: 34288015
[TBL] [Abstract][Full Text] [Related]
14. The expression of androgen-responsive genes is up-regulated in the epithelia of benign prostatic hyperplasia.
O'Malley KJ; Dhir R; Nelson JB; Bost J; Lin Y; Wang Z
Prostate; 2009 Dec; 69(16):1716-23. PubMed ID: 19676094
[TBL] [Abstract][Full Text] [Related]
15. Androgen regulated genes in human prostate xenografts in mice: relation to BPH and prostate cancer.
Love HD; Booton SE; Boone BE; Breyer JP; Koyama T; Revelo MP; Shappell SB; Smith JR; Hayward SW
PLoS One; 2009 Dec; 4(12):e8384. PubMed ID: 20027305
[TBL] [Abstract][Full Text] [Related]
16. Androgen receptor roles in the development of benign prostate hyperplasia.
Izumi K; Mizokami A; Lin WJ; Lai KP; Chang C
Am J Pathol; 2013 Jun; 182(6):1942-9. PubMed ID: 23570837
[TBL] [Abstract][Full Text] [Related]
17. A rare castration-resistant progenitor cell population is highly enriched in Pten-null prostate tumours.
Sackmann Sala L; Boutillon F; Menara G; De Goyon-Pélard A; Leprévost M; Codzamanian J; Lister N; Pencik J; Clark A; Cagnard N; Bole-Feysot C; Moriggl R; Risbridger GP; Taylor RA; Kenner L; Guidotti JE; Goffin V
J Pathol; 2017 Sep; 243(1):51-64. PubMed ID: 28603917
[TBL] [Abstract][Full Text] [Related]
18. Epithelial-to-mesenchymal transition and estrogen receptor α mediated epithelial dedifferentiation mark the development of benign prostatic hyperplasia.
Shao R; Shi J; Liu H; Shi X; Du X; Klocker H; Lee C; Zhu Y; Zhang J
Prostate; 2014 Jun; 74(9):970-82. PubMed ID: 24752964
[TBL] [Abstract][Full Text] [Related]
19. Regional variations of insulin-like growth factor I (IGF-I), IGF-II, and receptor type I in benign prostatic hyperplasia tissue and their correlation with intraprostatic androgens.
Monti S; Di Silverio F; Iraci R; Martini C; Lanzara S; Falasca P; Poggi M; Stigliano A; Sciarra F; Toscano V
J Clin Endocrinol Metab; 2001 Apr; 86(4):1700-6. PubMed ID: 11297606
[TBL] [Abstract][Full Text] [Related]
20. The Role of Heat Shock Protein 70 Subfamily in the Hyperplastic Prostate: From Molecular Mechanisms to Therapeutic Opportunities.
Fu X; Liu H; Liu J; DiSanto ME; Zhang X
Cells; 2022 Jun; 11(13):. PubMed ID: 35805135
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]